In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

King to sell Pain Therapeutics' abuse-resistant oxycodone; terminated

Executive Summary

Specialty pharma company King Pharmaceuticals paid $150mm in cash up front to Pain Therapeutics (PT) for a worldwide license (outside of Australia and New Zealand) to Remoxy, PT's abuse-resistant, long-acting oxycodone in Phase II trials for moderate-to-severe chronic pain. The companies also agreed to co-develop other abuse-resistant opioids including hydrocodone, hydromorphone (PTI202), and oxymorphone, all at the preclinical stage.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies